|
Basic Characteristics of Mutations
|
|
Mutation Site
|
E484K |
|
Mutation Site Sentence
|
Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro. |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
B.1.351;P.2 |
|
Viral Reference
|
-
|
|
Functional Impact and Mechanisms
|
|
Disease
|
-
|
|
Immune
|
- |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
- |
|
Treatment
|
bamlanivimab;casirivimab |
|
Location
|
Germany |
|
Literature Information
|
|
PMID
|
34223909
|
|
Title
|
Limited Neutralization of Authentic Severe Acute Respiratory Syndrome Coronavirus 2 Variants Carrying E484K In Vitro
|
|
Author
|
Widera M,Wilhelm A,Hoehl S,Pallas C,Kohmer N,Wolf T,Rabenau HF,Corman VM,Drosten C,Vehreschild MJGT,Goetsch U,Gottschalk R,Ciesek S
|
|
Journal
|
The Journal of infectious diseases
|
|
Journal Info
|
2021 Oct 13;224(7):1109-1114
|
|
Abstract
|
Whether monoclonal antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern has been investigated using pseudoviruses. In this study we show that bamlanivimab, casirivimab, and imdevimab efficiently neutralize authentic SARS-CoV-2, including variant B.1.1.7 (alpha), but variants B.1.351 (beta) and P.2 (zeta) were resistant against bamlanivimab and partially resistant to casirivimab. Whether antibodies are able to neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variantshas been investigated using pseudoviruses. We show that authentic SARS-CoV-2 carrying E484K were resistant against bamlanivimab and less susceptible to casirivimab, convalescent and vaccine-elicited sera.
|
|
Sequence Data
|
MW822592;MW822593
|